Clinical trials: Dementia of Alzheimer Type
Mild Cognitive Impairment, Dementia, Mild
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
The goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia.
- Trial name
- EVANTHEA (NCT05894954)
- Testing
- Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alzheimer's Prevention and Reversal Project, Inc.
Alzheimer's Disease
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
- Trial name
- NCT00203320
- Testing
- etanercept given by perispinal administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tobinick, Edward Lewis, M.D.
Coronary Artery Disease, Diabetes Mellitus, Type 2
PIPAF Platelets in the Pathogenesis of Ageing Associated Frailty
This is a prospective observational study aimed at testing the existence of an association between frailty, inflammatory status, and degree of platelet activation and reactivity in elderly subjects with type 2 diabetes or…
- Conditions
- Coronary Artery Disease, Diabetes Mellitus, Type 2, Alzheimer Disease
- Trial name
- PIPAF (NCT05798637)
- Testing
- Standard of care
- Where
- 2 sites in Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera di Perugia
Alzheimer Disease
Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the optimal dose(s) to be used in…
- Trial name
- Sirocco (NCT00501111)
- Testing
- AZD3480, Donepezil
- Where
- 70 sites in Austria, Belgium and 8 more
- Volunteers
- 659 people
- Sponsor
- AstraZeneca
Amyloid, Cardiac Amyloidosis
Amyloidosis Incidence in High-Risk Cardiac Device Patients
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation.
- Conditions
- Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis
- Trial name
- NCT06186167
- Testing
- Chest Wall Fat Tissue Collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Midwest Heart & Vascular Specialists
Agitation in Patients With Dementia of the Alzheimer's Type
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with…
- Trial name
- NCT04464564
- Testing
- AVP-786
- Where
- 106 sites in United States, Belgium and 11 more
- Volunteers
- 241 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dementia of the Alzheimer Type
Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI
The study aims to detect the effect of a structured cognitive rehabilitation program, teh stage specific intervention STACog, on cognitive performance and functional activation in fMRI in a group of patients with mild cognitive…
- Trial name
- ECIF (NCT01329601)
- Testing
- StaCog, stage specific cognitive Intervention, booklet based training
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- University of Rostock
Alzheimer's Disease
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate.
- Trial name
- NCT00090116
- Testing
- Neramexane
- Where
- 34 sites in United States
- Volunteers
- 400 people
- Sponsor
- Forest Laboratories
Alzheimer Disease, Dementia; Alzheimer's Type (Etiology)
Effects of Strength Exercise on Fall Risk in Elderly With Alzheimer's Disease
Interventional study to show the effects of strength exercise on fall risk in elderly with Alzheimer's disease
- Conditions
- Alzheimer Disease, Dementia; Alzheimer's Type (Etiology), Fall Risk, Elderly
- Trial name
- NCT04981587
- Testing
- Strength exercise, Usual treatment
- Where
- 2 sites in Spain
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Jaén
Alzheimer's Disease
Nefiracetam in the Treatment of Alzheimer's Disease
Some of the thinking difficulties of Alzheimer's patients may be due to a deficiency in a brain chemical called acetylcholine, which helps transmit messages between nerve cells.
- Trial name
- NCT00001933
- Testing
- Nefiracetam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Alzheimer Disease, Dementia
Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation
Globally, >47M individuals live with dementia, with new incidence of 7.7M annually. Medication mismanagement is one of the most common and concerning risk factors in people with dementia (PwD), as it leads to undertreatment…
- Conditions
- Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT06691256
- Testing
- HiDO-ALZ
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- HiDO Technologies
Dementia, Alzheimer Type
Project COPE:Managing Dementia at Home
This study tests the effectiveness of an in-home intervention to reduce upset and burden among family caregivers, and decrease nursing home placement.
- Trial name
- NCT00259454
- Testing
- In-home intervention
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Alzheimer's Type Dementia, Cognitive Decline
The Effectiveness of Global Postural Reeducation on Alzheimer Disease Patients
This research study is developed on an experimental design with randomized controlled intervention were participated 135 subjects with AD including 45 of the control group.
- Conditions
- Alzheimer's Type Dementia, Cognitive Decline, Postural; Strain
- Trial name
- GPR (NCT03732053)
- Testing
- GPR Intervention Research group
- Volunteers
- 135 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Addressing Dementia Via Agitation-Centered Evaluation
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
- Trial name
- ADVANCE (NCT03226522)
- Testing
- AXS-05, Bupropion
- Where
- 78 sites in United States, Australia
- Volunteers
- 366 people
- Sponsor
- Axsome Therapeutics, Inc.
Cognitive Impairment, Mild, Dementia, Mild
Tau PET Outcomes With Anti-amyloid Immunotherapies
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
- Conditions
- Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
- Trial name
- NCT06723015
- Testing
- 18F-AV-1451
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Mayo Clinic
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjects with agitation associated…
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
- Trial name
- ACCORD (NCT04797715)
- Testing
- AXS-05
- Where
- 63 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Axsome Therapeutics, Inc.
Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with…
- Conditions
- Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
- Trial name
- NCT00208819
- Testing
- risperidone, quetiapine, olanzapine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Emory University
Disseminated Sclerosis
A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).
In multiple sclerosis (MS) sub cortical cognitive impairments are frequently reported. Nevertheless, cortical cognitive troubles, with hippocampic memory troubles have been described.
- Trial name
- BioCogS (NCT00978536)
- Testing
- Cognitive impairment of multiple sclerosis
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital